<DOC>
	<DOCNO>NCT00574249</DOCNO>
	<brief_summary>The objective study assess efficacy safety adalimumab combination topical psoriasis treatment , calcipotriol/betamethasone , vs. adalimumab combination match vehicle subject moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Adalimumab Combination With Topical Treatment ( Calcipotriol/Betamethasone ) Subjects With Moderate Severe Psoriasis Insufficient Response Classic Systemic Treatment</brief_title>
	<detailed_description>Additional information regard sponsor : Abbott GmbH &amp; Co. KG sponsor EU member state . Abbott US sponsor non-EU member state .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subject &gt; = 18 year age Subject clinical diagnosis chronic plaque psoriasis least 6 month , moderate severe plaque psoriasis Subject must treat failed respond , contraindication , intolerant least two different systemic therapy , one must cyclosporine , methotrexate oral PUVA Subject judge generally good health determine principal investigator Subject previous exposure adalimumab Subject discontinue systemic therapy and/or topical therapy treatment psoriasis avoid UVB PUVA phototherapy Subject take require oral injectible corticosteroid Subject diagnose erythrodermic psoriasis , pustular psoriasis , medicationinduced medicationexacerbated psoriasis new onset guttate psoriasis Subject consider investigator , reason , unsuitable candidate Female subject pregnant breastfeeding consider become pregnant Subject calcium metabolism disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Moderate Psoriasis</keyword>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Severe Chronic Plaque Psoriasis</keyword>
</DOC>